Servatus is developing treatments for autoimmune disorders, including rheumatoid arthritis, ulcerative colitis and psoriasis.
Autoimmune conditions arise when the body’s immune system attacks its own healthy tissue as if it were foreign. Up to 8% of the population worldwide is affected by an autoimmune disorder, and this number is expected to rise over the next few decades.
Servatus’ research is based around rigorous scientific evaluation to better understand the mechanism of action of selected bacteria that can be used to develop highly defined medicines.
Bacteria can be manipulated or altered to produce versions with increased potency and efficiency. These select bacterial strains can be used to modulate disease trajectory; reduce signs and symptoms; and induce recovery.
Microbes and their genetic capability are collectively termed the microbiome, which plays an integral role in the development, education and maintenance of the human immune system.